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Abstracts of Invited and Proffered Papers
Recent advances in diagnostic cytochemistry
O.A.N. Husain
Cytology Departments, Charing Cross and St.
Stephen's Hospitals, London
In order to achieve a clearer recognition of the
neoplastic cell we have been pursuing a number of
lines of cell function which include: (1) The state of
the DNA. If the feulgin hydrolysis schedule is
slowed down a more labile component of the DNA
is recognised in the malignant and premalignant
nucleus and this phenomenon exists to a lesser
extent in the surrounding benign cells. (2) When
studying the glucose-6-phosphate dehydrogenase
activity in both cryostat sections and fresh smears
in an atmosphere of either oxygen or nitrogen it is
found that the presence of oxygen inhibits the
reduction of neotetrazolium chloride by blocking
the reducing equivalents, thus making a clear
distinction between malignant and benign lesions.
(3) The study of the lysosomal enzyme
naphthylamidase in both sections and smears has
demonstrated a significant increase in activity in
cells from invasive as opposed to benign lesions.
Tumour markers; where do we go now?
K.D. Bagshawe
Department of Medical Oncology, Charing Cross
Hospital, London, W6 8RF
The past 25 years have seen changing horizons for
tumour markers. Whilst the first recognized
markers have fulfilled expectations for a few
uncommon tumours good serological markers for
the common cancers are still awaited. Yet the
demonstration of both secreted antigens and cell
surface markers by immunocytochemistry, which
seemed to have little clinical application at first has
stimulated the imagination. With the monoclonal
revolution we are seeing wide recognition of the
potential of this technique and already it is a
principle test system for any new marker. With
antibodies showing specificity on histological
sections translation to the in vivo situation has
followed. Many questions are posed by the
technique of radioimmunodetection but already it is
showing clinical usefulness in certain situations. The
concept of antibody based delivery systems for
lethal agents is not new. Precise knowledge of the
distribution of antigenic targets and antibodies
directed at them in vivo is desirable not only for
ethical reasons but also in the choice of lethal
agents. There are possibilities of further improving
the discrimination of antibody delivery systems and
although obstacles are evident none, as yet, appear
unsurmountable.
CT in the diagnosis of cancer
L. Kreel
Radiology Department, Queen Mary's Hospital for
the East End, Stratford, London E15 and Wellington
Hospital, London NW]
CT shows soft tissue lesions larger than 0.5-1.Ocm
and is used mainly in the brain, mediastinum and
abdomen but is also applicable to lungs and bone.
In cancer the primary diagnosis has usually been
made; CT is used for staging particularly in
detecting unsuspected stage III and IV disease,
especially lymphadenopathy and pulmonary
metastases and usually upgrades the staging. The
size of the tumour can be accurately determined as
can the volume. In the brain, a tumour can be
distinguished from surrounding oedema. Incidental
or consequential pathology is frequently uncovered.556 ABSTRACTS OF INVITED AND PROFFERED PAPERS
Tumours are also accurately localised allowing
percutaneous aspiration, cytology or biopsy.
Accurate radiotherapy planning becomes possible
as well as monitoring tumour response to
treatment. Solid masses can be distinguished from
cysts and abscesses but neither the degree of
malignancy is discernible nor a sterile residual mass
can be distinguished from an active lesion. CT is
particularly valuable in detecting recurrent disease,
especially in lymphoma testicular tumours and
colon carcinoma.
Scanning for tumours with radio labelled antibodies
P.W. Dykes
The University ofBirmingham, Birmingham
Radio-labelled antibodies to tumour related antigen
concentrates in human cancer at 1-5 times the level
obtained in normal tissue. By the use of computer
based isotopic subtraction techniques, tumour
deposits greater than 2 cm diameter have been
demonstrated consistently in a number of human
malignancies. Anti CEA localises well in primary
and secondary colonic cancer, as well as in
carcinoma of the stomach, pancreas and naso-
pharynx. The use of a fetoprotein (ocFP) has
enabled detection of secondary deposits of germ cell
tumours not detectable by other means, where the
subsequent therapy has reversed a rising cxFP
concentration. The technique has recently been
applied to hormone secreting tumours, and of eight
patients with follicular thyroid tumours, 21
"abnormal areas" were demonstrated in seven and
of these, four could not be shown by other
techniques. Uptake could not be attributable to free
iodide. Tumour localisation has also been obtained
in two patients with islet-cell tumours of the
pancreas (diameter 1.5 and 2cm) using a polyclonal
anti-insulin. Monoclonal antibodies have also been
used in several centres, so far with similar localising
ability. Pilot studies have also been undertaken with
positron emitting isotopes for thyroid identification
using two facing integrated wire grid detectors.
Nuclear magnetic resonance in cancer diagnosis
D.M. Kean', B.S. Worthington', R.C. Hawkes2,
G.N. Holland2 & W.S. Moore2
'Department of Radiology and 2Department of
Physics, University ofNottingham
In 1971 Damadian described abnormal magnetic
relaxation times in neoplastic tissues. In 1973
Lauterber applied this knowledge in combination
with techniques of imaging formation, to form
images of neoplastic tissues. Since these initial
discoveries, a large amount of work has been
performed world-wide in the development of NMR
systems and their application to medicine, including
cancer. The initial hope that the precise histology
type could be achieved by simply analysing the
relaxation times has not lived up to all its
expectations. In radiotherapy, the facility to
accurately define and measure volumes easily is
very useful, both in planning the treatment and
assessing response to therapy. NMR is non-invasive,
and uses non-ionizing radiation. A possible
disadvantage is that no contrast medium is
available yet. Future developments will include the
search for a possible contrast agent, and further
analysis of relaxation time, especially the T2 values,
is required.
Incidence and prognostic significance of fiHCG-
positive giant cells in seminoma
J.R.W. Masters, D.N. Butcher & C. Parkinson
Dept. of Pathology, Institute of Urology, St. Paul's
Hospital, 24 Endell Street, London, WC2
Studies using either haematoxylin and eosin or
immunoperoxidase-stained sections show little
agreement regarding the incidence and have not
established the prognostic significance of
syncytiotrophoblastic elements in seminoma. From
a series of 177 seminomas received by the British
Testicular Tumour Panel and Registry between
Table
Incidence
Pathological HCG+ve Proportion dead ofdisease
stage cells HCG+ve HCG -ve Total
P1 12/103(11.7%) 2(16.6%) 12(13.2%) 14(13.6%)
P2 7/ 74( 9.5%) 3(42.9%) 13(19.4%) 16(21.6%)ABSTRACTS OF INVITED AND PROFFERED PAPERS 557
1958-1970 and followed for a minimum period of 7
years, paraffin sections were stained by a peroxidase
antiperoxidase technique using a primary antibody
directed against the fi subunit of human chorionic
gonadotrophin. The sections were examined
independently by two observers. The incidence of
syncytial giant cells was greater than commonly
reported, and no significant difference was observed
between tumours of different pathological stages
(see Table). A higher proportion of patients with
stage P2 lesions who died of the disease had
tumours containing HCG+ve cells, but these
figures did not attain statistical significance.
The Centocor CA 19-9Tm assay as a tumour marker
system for colorectal cancer
R.H.J. Begent, S. Dass, A. Smith & K.A. Chester
Department of Medical Oncology, Charing Cross
Hospital, London W6 8RF
Monoclonal antibodies have been raised against a
colorectal carcinoma cell line which reacts with a
carbohydrate antigen in cells of gastrointestinal
carcinomas (Koprowski et al., 1981, Science, 212,
53). One such antibody (19-9) has been used to
produce the Centocor carbohydrate antigen 199.TM
(CA 19_9Tm) radioimmunoassay (Sears et al., 1982,
J. Clin. Immunol., 2, 141). We have investigated this
assay as a tumour marker system in colorectal
cancer and compared it with carcinoembryonic
antigen and clinical parameters. CA 19-9TM values
were elevated in 5 of 20 patients before resection of
primary colorectal carcinoma. CEA was also raised
in 3 of these but in none of the other 15 patients.
CA 19_9TM was raised in 5 of 8 patients with
disseminated or recurrent disease whereas CEA was
raised in 7. Fifteen patients were studied serially
after apparently curative resection. Four relapsed
clinically. Relapse was predicted by CA 19-9 in
one, by CEA in 3 and by neither test in the
remaining patient. Three patients had persistently
raised CA 19_9TM post operatively without a
persistently raised CEA or clinical recurrence. All
three are at risk of recurrence on the basis of
Dukes' grading ± pre-operative CEA levels. Raised
values were found in 2 out of 20 patients with non-
malignant diseases. CA 19_9TM correlates with
disease status in a proportion of patients with
colorectal cancer. It is not suitable for screening but
may be useful in addition to CEA as a prognostic
indicator, in prediction of relapse and as a monitor
of therapy.
Prostaglandins in human breast cancer
D.M.A. Watson, R.W. Kelly', R.A. Hawkins &
W.R. Miller
University Department of Clinical Surgery, Medical
School, 1Centre for Reproductive Biology, Chalmers
Street, Edinburgh.
Human breast tumours may produce substantial
amounts of prostaglandin-like material (Bennett et
al., (1975), Lancet, i, 1218; Rolland, (1980), J. Natl
Cancer Inst., 64, 1061). These studies have been
based on measurements using bioassay and radio-
immunoassay. We now report the measurement
of prostaglandins (PG) by Gas Liquid
Chromatography Mass Spectrometry (GLC-MS)
in extracts of human breast tumours. One hundred
human breast tumours were homogenized and
extracted with ethanol. The extracts were
derivatized and levels of PGE2 and PGF2ac were
measured by GLC-MS. All tumours contained
measurable amounts of prostaglandins but wide
variations between individual tumours were found.
Concentrations for PGE2 varied from 7-762ngg-1
tissue (Median= 100). Those for PGF2a varied from
3-475ngg-1 tissue (Median=60). No statistical
correlation between the level of tumour PG and
either oestrogen or progesterone receptors was
observed.
Prognostic factors in locally recurrent rectal cancer
treated by radiotherapy
R.D. James, B. Eddleston, R. Johnson & G. Zheng
Departments of Radiotherapy and Radiodiagnosis,
Christie Hospital and Holt Radium Institute,
Manchester, M20 9BX
The response and survival of 143 patients treated
for locally recurrent rectal cancer using
radiotherapy alone have been analysed. The volume
of tumour in the pelvis has been measured using
CAT scanning in 45 patients and in 21 this was
repeated three months following treatment. CAT
scanning was extremely useful in the delineation of
tumour for planning purposes, but there was no
relationship between response and radiotherapy
dose, tumour volume or changes in volume
following treatment. There was a strong relationship
between early response and its duration, as well as
with probability of survival. There was also a
strong correlation between latent interval and
survival. It is concluded that response duration in
this condition following radiotherapy is independent558 ABSTRACTS OF INVITED AND PROFFERED PAPERS
of tumour volume and dose, and is largely
determined by the growth-rate of each tumour. This
fact should be taken into account in the
management of primary rectal cancer using
radiotherapy.
The significance of circulating immune complexes
(CIC), carcinoembryonic antigen (CEA) and immune
complexes containing CEA (CEA-IC) in patients
with colorectal cancer
K.A. Chester & R.H.J. Begent
Department of Medical Oncology, Charing Cross
Hospital, Fulham Palace Road, London W6 8RF
CIC have been proposed as a tumour marker
system, and there is evidence that CEA may be an
antigen component of CIC found in patients with
colorectal cancer.
CIC concentrations were measured in 31 patients
with known disease, and 11 had elevated CIC
concentrations. Of 15 patients followed serially after
apparently curative resection, 7 showed clinical
recurrence of disease and IC were elevated in 5 of
these whilst CEA was elevated in 2. CIC were also
raised in 2 patients who remained clinically well.
CEA predicted clinical relapse in 4/7 patients, and
in 2 of these CIC levels were elevated prior to CEA.
To investigate the possibility that CIC found in
these patients contained CEA as an antigen
component a new assay, based on perchloric acid
extraction of PEG precipitated and acid dissociated
complexed CEA was employed. CEA-IC were
shown to be present in model complexes but were
not found in 30 patients with known disease, 6 of
which were examined serially.
CIC may augment CEA as an indicator of
disease recurrence in colorectal cancer but may also
be elevated in patients without known disease,
probably due to the non-specificity of current CIC
assays. An antigen directed CEA-IC assay suggested
that the CIC detected did not contain CEA.
The elimination of carcinoma cells from human bone
marrow
R. Buckman', R.A.J. Mcllhinney', V. Shepherd2,
R.C. Coombes" 2 & A.M. Neville'
'Ludwig Institute of Cancer Research and 2Royal
Marsden Hospital, Sutton, Surrey SM2 5PT
Autologous bone marrow transplantation is an
important adjunct to high-dose cytotoxic therapy
and duration on neutropaenia is reduced if bone
marrow (BM) is first harvested and then reinfused
after the cytotoxic agent has been excreted. If,
however, the BM is infiltrated by malignant cells,
these may form a source for future relapse when
reinfused. We have therefore investigated techniques
for "cleaning-up" BM prior to reinfusion.
The mouse monoclonal antibody
LICR.LON.FIB-75 is an IgG2a recognising an
antigen present on all differentiated tumour cell
lines, on all breast cancer and their effusions
studied, on most normal differentiated tissues and,
in the BM, on granulocytes, myeloid cells,
erythrocytes but not lymphoid cells. It produces
complement-mediated cytotoxicity with human and
rabbit complement (RC'). Using a highly clonogenic
(50% cloning efficiency) cell line (EJ) we found that
FIB-75 could eliminate all tumour colony-forming
cells in BM up to an infiltration of 1% (105 EJ cells
in 107 BM cells).
The RC' used is absorbed against human cells
and in the concentrations used depresses the
granulocyte-committed stem cells (CFU-Cs) to 62%
of control values (26-100% N=24). The clean up
technique has been tested on large-scale in patients
and may prove to be an important aid in the
management of solid tumours, particularly of breast
and bronchus.
Correlation between histological grading and steroid
content in carcinoma of the prostate
R. Ghanadian & C.M. Puah
Prostate Research Laboratory, Royal Postgraduate
Medical School, Ducane Road, London W12 OHS
The relationship between endogenous testosterone
(T), 5a-dihydrotestosterone (DHT), Sa-androstane-
3a, 17f,-diol (diol) androstenedione (dione),
progesterone (P) and oestradiol-17fl (E2) with the
grading of prostatic tumours was investigated in 36
patients with malignant prostates. Tumours were
graded according to the degree of differentiation of
the malignant cells and the hormonal contents in
each tumour were measured by radioimmunoassays
developed in our laboratory. When the hormone
results were correlated to the different grades of
malignancy, the well to moderately differentiated
tumours were found to contain significantly lower
levels of T (P<0.01), dione (P<0.01) and P
(P<0.01) than the poorly differentiated malignant
prostates. In contrast there were no significant
differences in the endogenous levels of DHT, diol orABSTRACTS OF INVITED AND PROFFERED PAPERS 559
E2 between these two histological groups. When the
percentage of the malignant cell present in each
tumour was analyzed in relation to the content of
endogenous steroids, only T revealed a significant
correlation (r=0.49, P<0.05). These findings are in
keeping with our previous report on the in vitro
metabolism of andogens in prostatic cancer in
which the oxidative pathway was found to be
associated closely with the more aggressive form of
tumour.
Localisation of human colorectal cancers using a
monoclonal antibody (791T/36)
P.A. Farrands', A.G. Perkins2, J.G. Hardy2, M.J.
Embleton3, M.V. Pimm3, R.W. Baldwin3 & J.D.
Hardcastlel
Departments of 'Surgery, 2Medical Physics and
3Cancer Research Campaign Laboratories,
University ofNottingham, Nottingham NG7 2RD
Sixteen patients, 7 with disseminated colorectal
cancer and 9 with localised primaries, were injected
intravenously with pyrogen-free monoclonal
antibody (791T/36) (Embleton et al., 1981, Br. J.
Cancer, 43, 482), labelled with 75 MBq 31'I. Image
enhancement was achieved using 99mTc red blood
cells and ll3mIn-transferrin.
Six out of seven patients with disseminated
tumours and all nine of the patients with primary
tumours showed preferential localisation of the
antibody to the tumour deposits, with a mean
target to non-target ratio of 4.2:1 (range 2.1:1 to
8.1:1). In one case a synchronous tumour was
accurately diagnosed pre-operatively where only
one was documented radiologically, and in another
secondary deposits were seen in the patient's brain
as well as the liver.
Imaging of the resected specimens in the nine
patients with primary tumours immediately after
their removal confirmed the localisation of the 3I-
labelled antibody to be in the cancer. Radioactive
counts of the '3 I-labelled antibody compared to
unlabelled 99mTc in these five specimens showed a
mean tumour to normal ratio of 4.2:1 (range 2.26:1
to 7.1:1).
Using a monoclonal antibody specific localisation
of primary as well as secondary tumours has been
recorded, and may have potential in terms of
tumour imaging and as a carrier for cytotoxic
drugs.
Human breast carcinoma detection using a
radiolabelled monoclonal antibody
R.M. Rainsburyl 2, C. Foster', R.C. Coombes"2,
J.C. Gazet2 & A.M. Neville'
Ludwig Institute for Cancer Research' and Royal
Marsden Hospital2, Sutton, Surrey SM2 5PT
A monoclonal antibody, LICR.LON.M8, has been
raised against human milk fat globule membrane
and has been found to bind to the majority of
human breast carcinoma cells. Purification of the
antibody has been carried out using Protein A
Sepharose, and optimal iodination conditions have
been determined utilising cell binding assays and
chromatography. Satisfactory labelling of the
antibody with I123 and I13' has been achieved.
Human breast and renal xenographs have been
established in several anatomical sites in immune
suppressed mice. Preferential localisation of
intravenously administered labelled antibody has
been demonstrated in these tumours in all sites. The
cellular level of localisation has been demonstrated
by combined immunocytochemistry and
autoiodiography. Simultaneously administered
control monoclonal antibody has failed to show
localisation.
A small number of patients with metastatic
breast carcinoma have been given 1123 labelled
antibody. Images obtained using computerised
emission tomography have been compared with
computerised axial tomograms, with favourable
correlation in 2 out of 6 patients.
Factors affecting compliance with screening for
colorectal cancer
P.A. Farrands, J. Chamberlain & J.D. Hardcastle
Department of Surgery, University Hospital,
Nottingham, and Institute of Cancer Research,
London
Faecal occult blood testing has been proposed as a
means of screening for colorectal cancer but
acceptance of the test has been disappointingly low:
27%-45%.
A random sample of 756 individuals, part of a
screening study of 10,000, were interviewed 2 weeks
before being sent the occult blood test and again 6
weeks later. 50.3% accepted and 49.7% refused.
24% of those refusing forgot to do the test, and
only 21% found the test unacceptable. Refusers
were less health conscious as evidenced by their560 ABSTRACTS OF INVITED AND PROFFERED PAPERS
scepticism about regular health checks (28% of
45%) and their failure to wear seat belts or seek
regular dental care. Less of the refusers had heard
of colorectal cancer, 84% compared with 92%, and
only 29% compared to 52% were able to list 3 or
more symptoms of colorectal cancer. Fifty-one
compared with 68% knew what a colostomy was.
More of those refusing felt cancer meant death (81
compared to 70%) and were frightened by cancer,
but 94% were prepared to read factual information
about cancer. Compliance was significantly greater
in the 45-49 year age group, and those individuals
in social class 1, in keeping with results from
screening studies in breast and cervical cancer (3).
Discriminant analysis indicated 34 questions were
highly significant (P=0.001) in predicting whether
an individual would perform the test, with a
predictive value of 98.3%.
It would seem likely that health education, and in
particular, increased knowledge about colorectal
cancer would increase compliance and, therefore,
greatly improve the effectiveness of screening
programmes.
Immunological defects in "cured" patients with
cancer
L. Bruce & B.W. Hancock
University Department of Mediciwt, Royal
Hallamshire Hospital, Sheffield. S10 2JF
We have previously reported (Hancock et al. (1977)
Br. J. Cancer, 36, 347; Hancock et al. (1979)
Cancer, 43, 118) the effects of treatment on the
immunocompetence of patients with Hodgkin's
-disease and carcinoma of the cervix uteri
immediately following treatment and at 12 months
follow up. Varying levels of humoral and cellular
immunoincompetence were found. Immunity has
now been reassessed in 27 patients with Hodgkin's
disease (HD), 5 with non-Hodgkin's lymphoma
(NHL) and 9 patients with localised carcinoma of
the cervix uteri (Ca Cx), following 5 years of
complete remission after radio- or chemotherapy.
Neutrophil counts fell after treatment in HD and
Ca Cx. In HD this fall persisted at 5 years
remission (mean 3.57+0.34 s.e. v mean 5.32+0.53
s.e. at presentation, P<0.05) but counts rose back
to presentation levels in Ca Cx. Lymphocyte counts
fell with treatment in all groups but were above
presentation levels in HD at 5 years (mean
2.48+0.29 s.e. v mean 1.70+0.10 s.e. at
presentation P<0.05). Neutrophil function (nitro-
blue tetrazolium test) was unchanged in remission
in all groups. In HD all immunoglobulin classes
showed falls during follow-up, low values of IgG
and IgM being a prominent feature in those
patients having splenectomy and chemotherapy.
Lymphocyte transformation and particularly
leucocyte migration inhibition tests demonstrated
a marked deterioration in cellular immunity at
5 years in all groups. Overall cellular
immunocompetence fell from 70% at presentation
to 33% at 5 years in HD, 60% at presentation to
40% at 5 years in NHL and 89% at presentation to
33% at 5 years in Ca Cx. Immunocompetence is
not therefore necessarily a marker of recurrence of
disease and the prolonged immunosuppressive
effects of therapy do not appear to adversely effect
the prognosis.
Anti-idiotypic antibody in the monitoring of patients
with B-cell lymphoma
F.R. MacBeth1, F.K. Stevenson2, G.T. Stevenson2
& J.M.A. Whitehouse1
'Department of Medical Oncology and 2Lymphoma
Research Unit, Tenovus Laboratory, Southampton
General Hospital, Southampton S09 4XY
Polyclonal IgG antibodies against the idiotypic
surface immunoglobulin (id) on lymphoma cells
from two patients with established B-cell lymphoma
were raised in sheep by a previously described
method (Stevenson et al. (1980), J. Exp. Med., 152,
1484. These anti-idiotypic antibodies (anti-id) were
then used to monitor disease progress in two ways
over a one year period: (i) The id-bearing
lymphoma cells in blood and bone marrow were
identified and counted using fluoresceinated anti-id.
(ii) Using the ELISA technique small quantities of
circulating free idiotype could be identified and
quantitated in the serum. In one patient with
predominantly bone marrow disease in apparent
remission there was a tenfold increase in free
idiotype levels (to c.50jugml-1) and a 3-fold
increase in id-bearing lymphoid cells in the blood
prior to overt haematological relapse. At relapse
40% of the bone marrow cells and 90% of blood
cells were id-bearing. A short course of oral
chemotherapy produced clinical remission and a
corresponding decrease in both parameters which
have been further monitored over a 6-month period
off treatment. In the second patient, with
progressive nodal disease, id-bearing cells (15% of
lymphoid cells) were identified in a morphologically
normal bone marrow specimen. The blood
population of id-bearing cells remained stable at
10-20% of lymphoid cells and free idiotype levelsABSTRACTS OF INVITED AND PROFFERED PAPERS 561
were low (c.5 jgml-1) and increased slowly, despite
local radiotherapy and oral chemotherapy. /2
microglobulin levels were assayed in both patients
and although there were changes, they were small
and not easily interpreted in relation to the clinical
state.
Monocyte complement receptor defect in lung cancer
M. Carroll, M.E. Hodson & A.B. Kay
Departments of Allergy and Clinical Immunology,
and Medicine, Cardiothoracic Institute, Brompton
Hospital, London.
Mononuclear phagocyte function is known to be
defective in certain forms of human malignant
disease including bronchial carcinoma (Kay &
McVie (1977), Br. J. Cancer, 36, 461). There is a
parallel between monocyte chemotaxis and the
ability of these monocytes to enhance the
expression of their C3b receptors when exposed to
a chemotactic agent (complement receptor
enhancement-CRE) (Kay et al. (1979), Clin. Exp.
Immunol., 38, 294). Using a rosette technique to
identify the C3b receptor we have studied 30
untreated patients with bronchial carcinoma of
varying histology and clinical stages. The control
group consisted of healthy individuals and patients
with non-malignant respiratory diseases. There were
no differences in the absolute number of C3b
receptors on the peripheral blood monocytes from
the cancer group as compared with controls.
However, when the monocytes were exposed to a
synthetic chemotactic agent, (f-met-leu-phe), the
normal enhancement of C3b receptors was defective
in those individuals with intrathoracic spread or
distant metastases. The degree of inhibition
appeared to be independent of the histological cell
type. Patients with localised disease did not show
the same defect. Thus CRE might have potential as
a useful laboratory test in predicting the
progression of the disease and possibly the response
to treatment.
Lysozyme content of breast cancer-Associated
macrophages
R.J.C. Steele, 0. Eremin, M. Brown & J. Ashby
Department of Clinical Surgery, University of
Edinburgh, Edinburgh
Lysozyme, which is present in varying amounts in
macrophages, may damage tumour cells (Osserman
et al. (1973), Nature, 243, 331) and can be regarded
as a measure of activation (Mason & Taylor (1975),
J. Clin. Pathol., 28, 124). In a study to characterise
the lysozyme content of breast cancer associated
macrophages, 16 patients and 14 comparable
controls were studied. Cells of the
monocyte/macrophage series were identified by
rosette formation using an antimacrophage
monoclonal antibody coupled to sheep erythrocytes
by chromic chloride, and by Fc rosettes using
IgG-coated ox erythrocytes. Lysozyme was identified
on cytocentrifuge preparations using an
immunoperoxidase system. The percentage of
rosetted blood monocytes containing lysozyme was
greater in cancer patients than in controls
(P<0.001). However, macrophages from tumour-
draining lymph nodes and those from control nodes
contained lysozyme in comparable numbers, and
both populations displayed a relative lack of the
enzyme when compared to blood monocytes
(P<0.001). Macrophages from tumours were
positive for lysozyme significantly less frequently
than both monocytes (P<0.001) or macrophages
from tumour-draining lymph nodes (P<0.05). It is
postulated that, in breast cancer patients, blood
monocytes are activated in terms of lysozyme
content, but this does not hold for nodal
macrophages, and tumour-infiltrating macrophages
are depressed, suggesting an impaired anti-tumour
capacity.
Specific detection of the placental-type isoenzyme of
alkaline phosphatase in human malignancy using a
monoclonal antibody
P.M. Johnson, P.J. McLaughlin & I.W. McDicken1
Depts. ofImmunology and 1Pathology, University of
Liverpool, P.O. Box 147, Liverpool, L69 3BX
A murine monoclonal antibody (mAb) has been
characterised and shown to be reactive with an
epitope expressed by the heat-stable L-
phenylalanine-inhibitable human placental-type
alkaline phosphatase (P1-ALP) but not by other
human ALP isoenzymes (McLaughlin et al. (1982),
Int. J. Cancer, 30, 21). This mAb (H317) reacts in
immunohistology with placental and chorionic
trophoblast, but not with other normal tissue. It
does, however, give membrane staining on a variety
of human tumour cell lines of ectodermal origin and
correlates with the histochemical detection of Pl-
ALP. Based on the H317 mAb, we have now
developed a sensitive and specific ELISA for Pl-
ALP that has a lower limit of detection of 0.1 U l-1.
No P1-ALP (i.e. <1 UI`) was detectable in 120562 ABSTRACTS OF INVITED AND PROFFERED PAPERS
normal plasma samples, whereas low levels (0.1-
4.7 U -l) were found in 20/177 plasmas from
unselected human malignancies. Within these, 17/43
(40%) from histologically-proven ovarian carcinoma
patients were positive; in contrast, no detectable
plasma P1-ALP was found in 32 breast carcinomas.
Nonetheless, all extracts prepared from 7 surgically-
removed breast carcinoma tissues and 3 ovarian
carcinoma tissues contained significant quantities of
P1-ALP. Moreover, positive immunoperoxidase
PAP staining using the H317 mAb was given by
carcinoma cells in sections from 10 fixed primary
breast carcinoma tissues. Thus, mAb's specific for
the P1-ALP isoenzyme type may be valuable for re-
assessing the usefulness of P1-ALP as a tumour
marker, particularly in ovarian carcinoma.
Immunocytochemical staining of cervical smears for
the diagnosis of cervical intraepithelial neoplasia
D. Moncrieff1' 2, M.G. Ormerod', & D.V. Coleman2
'Institute for Cancer Research, Haddow
Laboratories, Clifton Avenue, Sutton, Surrey and
2Department of Pathology, St. Mary's Hospital
Medical School, Praed Street, London W2
One hundred and ten cervical smears were stained
by immunocytochemical methods for epithelial
membrane antigen (EMA) and compared with
Papanicolaou stained smears from the same women.
Squamous epithelial cells from normal cervices did
not stain but cells shed from cervices with cervical
intra-epithelial neoplasia (CIN) did express the
marker. This is a new method for detecting cervical
intraepithelial neoplasia in vitro and may be of use
in an automated screening programme.
Human wart virus infection and cervical cancer
M. Walker, D. Cheetham, M.L. Anderson, C.
Pomfret & D. Coleman
Department of Pathology, St. Mary's Hospital
Medical School, Praed Street, London W2
Seventy women with abnormal cervical smears
showing changes suggestive of cervical
intraepithelial neoplasia were investigated for
evidence of human papillomavirus infection of the
uterine cervix. Colposcopic examination revealed
changes suggestive of wart virus infection in 14
cases. Histological evidence of wart virus infection
was seen in paraffin embedded section of
colposcopic biopsy material in 36 patients.
Immunocytochemical studies of histological
material was carried out on 27 biopsies using an
antiserum specific for papillomavirus antigen.
Papillomavirus antigen was demonstrated in 11
cases. These observations are discussed in relation
to recent reports implicating human
papillomaviruses in the genesis of cervical cancer.
Sialylation of breast cancer surface determinant
identified by monoclonal antibody LICR-LON-M18
C.S. Foster
Ludwig Institute for Cancer Research (London
Branch), Royal Marsden Hospital, Sutton, Surrey,
SM2 5PX
Using the human milk fat globule membrane as
immunogen, a panel of monoclonal antibodies has
been generated that, within the normal breast,
specifically bind to the luminal plasma membranes
of the epithelial cells (Foster et al. (1982), VKrchow's
Archiv., 394, 279). Antibody LICR-LON-M18 was
found to bind infrequently to all breast carcinomas
(Foster et al. (1982), VIrchow's Archiv., 394, 295).
Analysis using the specific glycosidase,
neuraminidase, has shown that the determinant is
not missing from breast cancer cells but is cryptic
due to masking by sialic acid. The epitope identified
by LICR-LON-M18 contains the immunodominant
carbohydrate sequence Gal P 1-.4 GlucNAcl-13
Gal. This epitope is a component of at least 6
glycoprotein bands extracted from human MFGM
and at least 3 glycoprotein bands extracted from
breast cancer plasma membranes. Three specific
differences in the processing and expression of this
determinant have been identified in breast
carcinomas: (i) Synthesis of the epitope appears
unimpaired although it is misprocessed and masked
by sialic acid. (ii) The determinant is not expressed
exclusively on the plasma membranes, but
frequently within the cytoplasm of breast duct
carcinoma cells.- (iii) In colloid breast carcinomas
the determinant is not retained but shed from the
tumour cells, and thus accumulates as a major
component of the mucinous stromal matrix.
Alteration in sialic acid content has previously been
implicated as a possible basis of tumour cell
heterogeneity (Zimmerman et al. (1976),
Biochemistry, 15, 5534). The misprocessing of the
LICR-LON-M18 determinant might regulate the
insertion of the complete glycoprotein molecules
into the tumour-cell plasma membranes and thus
modulate such phenomena as cell-cell recognition
and tumour-cell behaviour.ABSTRACTS OF INVITED AND PROFFERED PAPERS 563
A hypothetical mechanism of immune regulation
produced by a2 macroglobulin
A. Alomran, B.K. Shenton, G. Proud & R.M.R.
Taylor
Department ofSurgery, University ofNewcastle upon
Tyne
Many investigators have shown the
immunoregulatory function of x globulins from
normal and pathological sera in both in vivo and in
vitro experiments (Cooperband (1976), Trans. Proc.,
8, 2). We have studied and characterised the
naturally occurring suppressive factors in cancer
sera and in normal plasma. Gel filtration studies
showed that a major region of suppressive activity
was associated with a2 macroglobulin.
x2M is one of the major protease inhibitors in
plasma and it was found that protease (trypsin and
chymotrypsin, thrombin, elastase) binding to a2M
was accompanied by increased ability to suppress
lymphocyte activity in M.L.R. (Hubbard (1981), J.
Immunol., 126, 292). We have shown that following
enzyme activation of ax2M a peptide is liberated
which is a potent inhibitor of lymphocyte reactivity
when assayed in both transformation and TEEM
tests using antigenic, mitogenic and allogenic
stimulation. We have characterised this suppressive
peptide as a single component on HLPC with a
mol wt of 3-4Kd which was identical to another
immunosuppressive peptide isolated from the
plasma of cancer patients. We suggest that this
substance may be of value as a biological
immunosuppressant.
Susceptibility of in vivo derived primary and
transplanted spontaneous tumours in the rat to lysis
by natural killer cells
G.R. Flannery, R.P. Arthur, B.L. Ferry & R.W.
Baldwin
Cancer Research Campaign Laboratories, The
University, Nottingham NG7 2RD
Natural killer (NK) cells have been suggested as
mediators of anti-tumour surveillance in vivo. In the
rat, animals developing spontaneous tumours show
no evidence of impaired NK activity, and these
tumours rarely induce augmented NK lysis
(Flannery & Brooks (1981), Int. J. Cancer, 28, 747).
These results argue against a surveillance type role,
but the relative NK resistance of metastatic
deposits of transplanted spontaneous tumours
(Brooks et al. (1981), Int. J. Cancer, 28, 191) may
reflect a selective pressure in vivo, and supports a
role for NK cell regulation of secondary tumour
spread. We have now studied the susceptibility to
NK lysis of cells freshly derived from a number of
rat tumours. Of 21 spontaneous tumours (14
primary and 7 transplanted lines), 18 were
significantly less susceptible to normal splenocyte
killing than cells from the in vivo derived reference
tumour Mc7, a 3-methylcholanthrene-induced
sarcoma. When chemically-induced lesions were
tested, 9/11 primary and 3/6 transplanted tumours
showed no evidence of such NK resistance. These
results suggest that NK cells might influence the
development of primary as well as secondary
spontaneous tumours in the rat, resulting in an in
vivo selection for tumour cells which are relatively
resistant to NK mediated lysis. As the majority of
spontaneous rat tumours are well differentiated and
derived from breast or kidney, these data are also
consistent with a role for NK cells in the control of
tumours of specific histological types or degrees of
differentiation.
Macrophage-like cells isolated from tumour
infiltrates inhibit natural killer cell activity
B.L. Ferry, G.R. Flannery & R.W. Baldwin
Cancer Research Campaign Laboratories, The
University, Nottingham NG7 2RD
Tumour-infiltrating lymphocytes, isolated by nylon
column elution from chemically-induced rat
sarcomas, exhibit natural killer (NK) cell activity in
vitro (Flannery et al. (1981), Cell Immunol., 61, 1).
When the 1-2% contaminating phagocytic cells are
removed from these effector cell populations by
treatment with carbonyl iron, natural cytotoxicity is
enhanced. This suggests that the infiltrate contain
macrophage-like suppressors of NK activity. Using
velocity sedimentation at 1 g on Percoll gradients, it
has been possible to isolate fractions of tumour-
infiltrating host cells from these tumours. One
fraction, of predominantly lymphoid morphology,
exhibits NK cytolytic activity comparable with that
of nylon column eluted cells. A second fraction,
enriched for macrophages, contained 55-65%
phagocytic cells. At least 95% of the cells in this
fraction also stain with the leucocyte common
monoclonal antibody MRC OX-1, indicating a low
tumour cell contamination. In admixture
experiments, cells from this second fraction
suppress the cytotoxicity of splenic NK cells and
preliminary data indicate a similar suppression of
the tumour-infiltrating NK cells. This suppressive564 ABSTRACTS OF INVITED AND PROFFERED PAPERS
effect is abrogated after removal of phagocytic cells
with carbonyl iron. These data then support the
contention that macrophage-like suppressors of NK
cell killing are present within the host infiltrate and
this may account for the low NK activity seen in
the infiltrates of both chemically-induced and
spontaneous rat tumours.
Growth of human kidney tumour xenografts in nude
mice (NU/NU) and nude rats (RNU/RNU);
production of antibodies against tumour cell surface
components
P.N. Matthews, A.G. Grant & J. Hermon-Taylor
Department of Surgery, St. George's Hospital
Medical School, London, SWJ7 ORE
The immunological identification of cell surface
determinants with a useful selectivity for one type
of human cancer is complicated by the large
numbers of other cell surface components common
to many cells. In the present study antibodies
directed against antigens released from human
tumour cells during xenograft growth were raised
by cross-immunization of immunocompetent hairy
litter mates (nu/+) with serum from nude mice
(nu/nu) bearing human kidney tumour xenografts.
Renal cell carcinomas from 11 patients were
implanted subcutaneously into a total of 51 nude
mice and 27 nude rats (rnu/rnu); 3 of these grew as
xenografts in both species. One of these renal
tumours ("GYL") has been established as a cell
line in tissue culture. Serum from 50 "GYL"
tumour-bearing nude mice was collected, pooled
and used to immunise 16 immune competent hairy
litter mates. The production of anti-GYL antibody
was monitored by an I125 binding assay in vitro
against cultured viable GYL cells using serum from
hairy littermates challenged with normal nu/nu
serum as a control. In 2 of the hairy litter mates,
cell surface antibody binding by GYL cells was
twice that found with any one of a panel of 8
different human tumour cell lines. Absorption of
these antisera with 1 x 107 "GYL" tumour cells
completely abolished this response, whereas 50%,
40% and 25% of activity remained after absorption
with normal kidney cells and a mixed pool of
human tumour cells respectively.
These results show that human kidney tumours
growing as xenografts in nude mice release cell
surface antigens into the serum and that cross
immunisation of their immune competent relatives
provides a strategy for the development of
monoclonal antibodies of useful selectivity.
Selection of monoclonal antibodies for clinical
tumour localisation
K. Sikora, H. Smedley, P. Finan, E. Lennox, A.
Ritson & P. Wraight
Ludwig Institute for Cancer Research, MRC
Laboratory for Molecular Biology and Dept. of
Nuclear Medicine, Cambridge. Dept. of Surgery,
Leeds
A set of monoclonal antibodies (MCA) were
obtained by fusing splenic lymphocytes from rats
immunised with membrane preparations from fresh
human colorectal cancer. Supernatants from 17
cloned hybridomas were found to bind strongly to
the colon carcinoma line HT29 by indirect
radioimmunoassay. Immunofluorescence using
these MCAs on sections of fresh frozen colon
carcinoma and normal tissue revealed different
staining patterns. Nine MCAs were purified by ion
exchange chromatography and labelled with 1311
using chloramine T. Groups of mice bearing HT29
xenografts were given 25jug of each MCA labelled
with 25/uCi of 131I. Eight of the 9 MCAs showed
tumour localisation as determined by rectilinear
scanning and by tumour to normal tissue
radioactivity ratios post mortem. The MCA
showing optimal localisation in vivo stained both
malignant and normal tissue equally on
immunofluorescence (YPC 2/38.8). Three MCAs
were evaluated clinically by scintiscanning patients
with metastatic colorectal carcinoma. YPH 2/38.8
failed to show tumour localisation whilst two other
antibodies which showed preferential tumour
staining patterns on immunohistology but had
performed less well on xenograft localisation gave
good tumour images. One antibody YPC 2/12.1 has
now been assessed in 30 patients. A combination of
binding assays, immunohistology and xenograft
localisation is clearly important in the selection of
MCAs for clinical use in tumour imaging.
A study of the immunological effects of priming
regimes
I.A. Fraser, V. Bowry, J. Collins & P.R.F. Bell
Department of Surgery, University of Leicester,
Leicester
The use of a small "priming" dose of cytotoxic
agents before major chemotherapy has recently
been described (Hedley et al. (1978), Lancet, 2,
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therapy to the marrow and gastrointestinal tract,
although its mechanism is not clear. Since immune
depression is a serious consequence of most
chemotherapy regimes, we have investigated the
possibility of immunological protection afforded by
such regimes using an animal model.
T cell function was measured in Sprague Dawley
rats by two methods. In vitro PHA blastogenesis
was studied by a whole blood technique and in vivo
delayed type hypersensitivity (DTH) using
oxazolone. One dose of a chemotherapeutic regime
was administered to groups of animals as follows:
cyclophosphamide, 5FU or CVMF (chlorambucil
vincristine methotrexate and 5FU). Each regime
produced clear depression of in vitro blastogenesis
over the subsequent month and in vivo DTH
response measured at 24h. The effect of priming on
this depression was investigated by a small dose of
cyclophosphamide 5 days before regimes 1 and 3,
and 5FU 5 days before regime 2. Groups of 20
animals simultaneously received one of the above
regimes, half having been primed as above and half
with saline as controls. No difference was observed
in the subsequent depression of T cell function. In a
further experiment using regime 1, the priming
delay was varied from 0-14 days in 7
simultaneously studied groups of 10 animals. No
difference was found in the subsequent immune
depression of any group. It is considered that
priming regimes are unlikely to confer protection to
T lymphocyte function in patients receiving cancer
chemotherapy.
The incidence of leukaemia in B cell neoplasia
A.H.M. Abdul-Cader, P.R. Richardson, L. Walsh,
I.C.M. MacLennan, M.J. Leyland, D.I. Gozzard,
E.L. Jones & N.R. Ling
East Birmingham Hospital; Department of
Immunology, and Department of Histopathology,
University ofBirmingham
Surface markers on blood lymphocytes were studied
in 186 untreated patients with B cell neoplasia and
correlated with the histopathological type of their
disease using the Kiel classification. All of the 46
patients with diffuse lymphocytic lymphoma had B
cell leukaemia, as defined by either >90% of B
cells expressing surface membrane kappa or >80%
expressing lambda. Of these, 39% had a total
lymphocyte count of <10/4ul-'. Twenty of the 65
patients with low grade follicle centre cell
lymphoma had B cell leukaemia. On the other hand
in myelomatosis only 1/35 had B cell leukaemia. In
this case the cells were morphologically identified as
plasma cells. In the lymphoplasmacytoid group the
incidence of B cell leukaemia was 5/18 whilst in the
high grade tumour group it was 3/22. This study
has shown that B cell leukaemia is a common
finding in low grade non-Hodgkin's lymphoma. It is
less common in patients with high grade tumours
and is not a feature of myelomatosis. In patients
without B cell leukaemia an absolute reduction in
blood B cell numbers was a common finding in all
groups in our series. The clinical significance of B
cell leukaemia or B lymphopenia associated with
the various histopathological types remains to be
determined. However, at this stage we can conclude
that the assessment of light chain expression in
blood lymphocytes in this group of diseases is an
extremely useful diagnostic aid.
Further advances in the management of malignant
teratomas of the testis and other sites
E.S. Newlands, R.H.J. Begent, G.J.S. Rustin, D.
Parker & K.D. Bagshawe
Department of Medical Oncology, Charing Cross
Hospital, Fulham Palace Road, London, W6 8RF
Analysis of 100 male patients with metastatic
malignant teratoma treated with sequential
combination chemotherapy between 1977 and 1982
projects an overall survival of 72%. Following
modification of the chemotherapy in 1979
(Newlands et al. (1980), Br. J. Cancer, 42, 378) the
survival in the last 69 patients entered in this study
projects a survival of 80%. This chemotherapy,
which alternates (a) vincristine, methotrexate,
bleomycin, cis-platinum with (b) VP 16-213,
actinomycin D and cyclophosphamide, has resulted
in the salvage of patients even with very advanced
disease. In complete remission are: 20/23 (87%)
advanced abdominal disease, 20/24 (83%) with
advanced lung disease, 11/19 (58%) with advanced
abdominal and lung disease, 9/11 (82%) with liver
metastases and 3/4 (75%) patients with brain
metastases. Survival by primary site was: testis
72/87 (83%), retroperitoneum 3/7 (43%),
mediastinum 3/4 (75%), unknown primary site 2/2
(100%). Multivariate analysis has identified two
important adverse prognostic factors: the initial
serum concentrations of human chorionic
gonadotrophin (hCG) >50000 iu 11 and/or
alpha-foetoprotein (AFP)>500ugl-1; prior radio-
therapy compromised prognosis (P=0.017). The
most important determinant is the clinical
concentration of hCG and/or AFP; in patients
presenting with serum concentrations below the566 ABSTRACTS OF INVITED AND PROFFERED PAPERS
levels defined above the survival in 60 patients is
92%; and in those with higher concentrations the
survival was 48% (P= <0.001).
Response of human cervical tumours to radiotherapy
determined by flow cytofluorometry
J.E.D. Dyson, J.B. MacLaughlin, C.R. Surrey &
C.A.F. Joslin
University Department of Radiotherapy, Cookridge
Hospital, Leeds LSJ6 6QB
The technique of flow cytofluorometry enables the
DNA and RNA content of individual cells, stained
with a fluorescent dye, to be determined as they
pass through a laser beam. By this means we are
determining the content of heteroploid cells, and
fraction of proliferative cells, in sequential biopsies
of cervical tumours, taken at approximately weekly
intervals, during a course of radiotherapy. Single
cell suspensions are prepared from the tissue
biopsies by disaggregation with collagenase, the
cells stained stained with acridine orange plus
ethidium bromide, then anlysed with an Ortho
Diagnostics Systems 50 Cytofluorograf, with
dedicated computer. All data are stored on disk for
comparison with the histopathology determined on
parallel biopsies, and ultimately to be compared
with the long-term results of the therapy, and the
progress of the patient. Results so far show that it
is possible to monitor the elimination of
heteroploid and proliferating cells during the course
of treatment. Thus a rapid assessment may be made
of the radiosensitivity of the tumour and the
response to therapy. Continued accumulation of
data should enable us to determine the extent to
which flow cytofluorometric data may be utilised in
the clinical management of cervical cancer, and
individual patient prognosis.
Adenocarcinoma of stomach, pancreas, biliary tract
and unknown origin treated with 5-FU, adriamycin,
mitomycin
G. Sangster', D. Cunningham2, A. Hutcheon3, M.
Soukop2, S. Kaye', C. McArdle2, K. CalmanI &
D. Carter2
1Dept. of Clinical Oncology, Glasgow University,
2Dept. of Oncology and Univ. Dept. of Surgery,
Glasgow Royal Infirmary, 3Woodend Gen. Hosp.,
Aberdeen
Eighty-one patients (57 male, 24 female), mean age
55.8 y, received 5-Fluorouracil (F) twice monthly,
Adriamycin (A) 3-4 weekly and Mitomycin-C (M)
6-8 weekly. Fifty-four had advanced gastric cancer
(mean ECOG performance status (PS) 2.1), 16
adenocarcinoma of unknown primary site (ACUP)
(mean PS 1.5) and 11 pancreatic or biliary cancer
(mean PS 1.6). Six patients (3 gastric, I ACUP, 2
biliary) died within 3 weeks of starting FAM. The
remaining 74 patients received at least 2 treatment
cycles unless clear progression occurred after the
first course and all are evaluable for response. In
the gastric group, 32 (59.3%) patients showed
disease progression (median survival (m.s.) 4
months), 6 (11.1%) were stable (m.s. 8.5 months),
10 (18.5%) had a partial response (PR) (m.s. 14.5
months) and 3 (5.6%) a complete response (CR)
(m.s. 11 months). All patients in the pancreatic and
biliary group showed progression (m.s. 3 months).
The ACUP group included one patient with PR in
a retroperitoneal mass, becoming CR with
continued treatment at 6 months, the response
being maintained at 18 months; 3 patients were
stable and the remaining 12 with ACUP showed
progression (m.s. 6 months). Of the 13 responders
in the gastric group, 11 showed a response at the
primary site while only 1 response was seen in a
total of 15 patients with bulk liver disease. Toxicity
was not severe, the major manifestation being
haematological (mean nadir WBC 2.5 x 1091-1,
mean nadir platelet count 90 x 1091-1). Alopecia
was common and gastrointestinal toxicity (nausea
and vomiting) was mild (mean grade 1.5). Overall
the response to FAM chemotherapy was
disappointing in this unselected patient population,
suggesting that alternative drug therapy should be
investigated as first line treatment for these forms
ofmalignancy.
Recombinant human interferon in advanced breast
cancer
H. Smedley, M. Katrak, K. Sikora & T. Wheeler
Ludwig Institute for Cancer Research, Cambridge
and Department of Radiotherapy, Addenbrookes
Hospital, Cambridge
The gene coding for human leucocyte A interferon
(IFN-a) has recently been isolated and cloned. We
have used a highly purified preparation of
recombinant IFN-a to study the efficacy and safety
of this preparation in patients with advanced breast
cancer. Twelve patients have received treatment
with either 50 million units m-2 i.m. three times
weekly or 20 million units m-2 i.m. daily for up to
12 weeks. A predictable pattern of side-effects has
emerged, and a previously undescribed syndrome ofABSTRACTS OF INVITED AND PROFFERED PAPERS 567
central nervous system toxicity with abnormal EEG
findings has been identified. This appears to be
dose-related and reversible, but has been dose
limiting in 4 patients. Five patients have had
objective regression of tumour, but only 2 have met
the UICC partial response criteria. Symptomatic
improvement has been noted by 6 patients.
Recombinant IFN-ox clearly has some biological
activity in patients with breast cancer and the trial
will continue to assess its effects in a large series of
patients.
Human tumour metastasis: Studies on patients with
malignant ascites treated with peritoneo-venous
shunts
D. Tarin', A.C. Vass2, R.G. Souter3, J.E. Price' &
B. Roach'
'Nuffield Dept. ofPathology, John Radeliffe Hospital
(Oxford Univ.), 2Dept. of Obstet. & Gynaecol.,
Wycombe General Hospital, High Wycombe, Bucks.,
3Nuffield Dept. of Surgery, John Radcliffe Hospital,
Oxford
The recent introduction of peritoneo-venous
shunting for treatment of intractable ascites due to
inoperable cancer has presented a unique
opportunity for observing factors affecting
metastatic spread of tumours in man. Since the
shunt is inserted solely for the relief of pain and
discomfort and investigative procedures are
confined to ones required for good routine clinical
management, the studies are ethically impeccable.
We present observations on nine patients with
primary tumours from a variety of sites, the
majority being ovarian. The minimum time of
survival was 2 months and the maximum 3 years.
Cells from the ascitic fluid and from the blood were
cultured, sometimes on several occasions, and
autopsies were performed on eight of the patients.
In some individuals no metastatic tumours formed
in any organs, despite the fact that the tumour cells
in the ascitic fluid were clearly viable and capable
of forming numerous seedling colonies on the
visceral and parietal peritoneum. Some of these
patients had survived up to 3 years after insertion
of the shunt and direct evidence of its patency was
provided by clinical observation, culture of cells
resembling tumour cells from the blood and
presence of latent tumour cells with indisputable
markers in many organs. Conversely, some patients
had widely disseminated seedling tumours of
uniform size in many organs within 2 months of
shunt insertion. In none of the patients was any
cellular immune response observed to deposits or
latent tumour cells. The manner of tumour cell
dissemination in these patients is the direct human
counterpart of that used in our studies on
metastatic colonisation potential of cells from
spontaneous murine mammary tumours. The
findings in the 2 species are so similar that we
tentatively conclude that at least some of the
underlying mechanisms in metastasis are common
to both.
Coliagenase secretion and spread of human tumours
D.J. Ogilvie', A.C. Vass2, E.G. Lee3 & D. Tarin'
'Nuffield Department of Pathology, (University of
Oxford), John Ratcliffe Hospital, Oxford;
2Department ofObstetrics & Gynaecology, Wycombe
General Hospital, High Wycombe, Bucks;
3Consultant Surgeon, John Radcliffe Hospital,
Oxford
There is a growing body of evidence that disruption
of connective tissue is an essential feature of
invasion and metastasis. In particular, destruction
of collagen fibres has been demonstrated in the
forefront of advancing tumours by electron
microscopy (Tarin (1967), Int. J. Cancer, 2, 195). In
vitro production of collagenase, which is so far the
only identified enzyme capable of such activity
under physiological conditions, has been correlated
with "metastatic" colonisation potential (Tarin et
al. (1982), Br. J. Cancer, 46, 266) for the MMTV-
induced mouse mammary tumour and with
temperature-dependent metastasis for the
amphibian Lucke renal adenocarcinoma (Ogilvie et
al., in preparation). We have, therefore, studied
certain human tumours to see whether collegenase
has a role in invasion and metastasis and to assess
its possible significance as a prognostic indicator.
We have so far studied 60 breast samples (including
15 benign lesions) and 20 samples of gynaecological
origin. These were all subjected to a primary
explant culture regimen and harvested fluids were
assayed for collagenolytic activity against [14C]-
radiolabelled, soluble, type I collagen. The viability
of cultured material was verified by glucose uptake.
The majority of breast tumours produce an enzyme,
satisfying the criteria of a "true" vertebrate
collagenase, which is mostly in a latent, trypsin
activatable form. Collagenase output is generally
high for benign tumours such as fibroadenomas
and low for benign cystic disease. For malignant
tumours, however, there is a wide quantitative
spectrum of collagenase elaboration which shows no
correlation with histological type. The question of
whether these findings are of prognostic value is
currently being evaluated in clinical trials.568 ABSTRACTS OF INVITED AND PROFFERED PAPERS
Levonantradol (LN) in the treatment of
chemotherapy induced nausea and vomiting,
refractory to conventional anti-emetics
R. Stuart-Harris, C. Mooney & I.E. Smith
Royal Marsden Hospital, London
LN, a synthetic agent structurally related to delta 9
tetrahydrocannabinol, is suggested in preliminary
reports as having anti-emetic activity in patients
receiving cancer chemotherapy. In an open Phase II
study the anti-emetic effect and toxicity of LN were
assessed in patients in whom chemotherapy induced
nausea and vomiting had proved intractable to
conventional anti-emetics. Twenty-two patients (15
female, 7 male; age range 20-70y) were treated
with LN in an initial dose of 0.5mg i.m. 4 hourly,
starting one hour before chemotherapy and
increasing if necessary to a maximum of 1.5mg.
One patient was not assessable for response as he
refused further LN after one dose because of side
effects. Of the 21 patients assessable for response, 2
(9%) had complete relief of nausea and vomiting, 7
(33%) good relief, 4 (19%) slight relief and 8 (38%)
no relief. Side effects were reported by all patients
and were worse with LN than with conventional
anti-emetics (P<0.001). Side effects were
drowsiness in 13 patients (59%), dizziness in 11
(50%), thought disturbance in 7 (31%), pain at
injection site in 5 (22%) and dry mouth in 3 (13%).
One patient developed severe but self limiting
drowsiness with disorientation after a total dose of
7mg in 36h. Nine patients (40%) had side effects
severe enough to reduce the dose or stop treatment.
In conclusion, LN is an effective anti-emetic in
approximately 50% of patients resistant to
conventional anti-emetics; however its usefulness is
likely to be restricted by side effects which are
common and frequently unpleasant.
Prospective cross over double-blind comparison of
MST continus 30mg and morphine sulphate solution
cancer patients with pain
J. Welsh', J.F.B. Stuart' 2, T. Habeshaw3, P.
Billiaert1, S.B. Kaye3 & K.C. Calman'
'Department of Oncology, University of Glasgow,
2Department of Pharmaceutics, University of
Strathclyde, 3Glasgow Institute of Radiotherapeutics
& Oncology
The aim of this study was to compare the efficacy
of 2 oral morphine preparations in the relief of
severe and intractable pain. Fifteen patients,
median age 56y, completed the trial. Stabilisation
on MST continus 30mg (MST-3) tablets was
achieved over a one week period. Patients were
randomised to receive MST-3 active + Morphine
sulphate solution (MSS) placebo or the reverse
regime. After 7 days treatment the alternate regime
was administered. Pain was assessed at intervals
during the 3-week period by means of a visual
analogue scale completed by the patients.
Approximate duration of sleep and both incidence
and intensity of side effects were recorded. Patients
were permitted additional analgestics if break-
through pain occurred. The results show MST-3 is
an effective analgesic. There appears to be no
difference in day or night pain control between
MST-3 and MSS given in equivalent doses. There
was no significant difference in the hours slept
when taking the elixir or tablets. The percentage of
patients developing side effects on the MST-3 and
MSS was similar. The side effects were as expected,
namely drowsiness, constipation, nausea, dizziness
and vomiting. There was no significant difference in
intensity of the side effects recorded (P>0.5). In
summary MST-3 appears to have similar analgesic
properties to that of equivalent doses of MSS. The
side effects and intensity of these are similar for the
two formulations. The advantage of the MST-3
preparation appears to be its twice daily regime and
the convenience its formulation offers in terms of
carriage by the patient.
The effect of chemotherapy on saliva and oral micro-
organisms
B.E. Main', K.C. Calman2, M.M. Ferguson', S.B.
Kaye2, T.W. MacFarlane', R.J. Mairs', L.P.
Samaranayake', J. Welsh2 & J. Willcox2
'Department of Oral Medicine and Pathology, and
2Department ofOncology, University ofGlasgow
Oral complications of chemotherapy result from
direct mucosal damage or, indirectly, as a
consequence of immunosuppression. Clinically there
is also thought to be xerostomia and impaired
taste. The aims of this study were to examine the
effects of chernotherapy on saliva volume and
composition (amylase, IgA and lysozyme). In
addition, changes in the oral microbial flora were
investigated. In the first study, healthy controls
were compared to patients receiving chemotherapy
for malignancies. This indicated that there were
differences between the two groups. However, there
were limitations on interpretation and a second
longitudinal study was initiated. Twenty patients,ABSTRACTS OF INVITED AND PROFFERED PAPERS 569
median age 46 y, were assessed before starting
chemotherapy and then again at one month and at
three months of treatment. The 10-min salivary
volume, amylase and IgA all fell significantly over
the 3-month period. Lysozyme did not alter. The
amount of candida isolated from saliva increased
with chemotherapy and there was a correlation
between salivary volume and candida score. A
range of other potentially pathogenic bacteria were
isolated from several of the patients, but not
controls. The conclusion is that chemotherapy
results in a decreased salivary flow, a lowering of
salivary amylase and IgA, and an increase in
opportunistic pathogens.
Reduced erythropoietin levels as a cause of the
anaemia of chronic disorders in patients with
malignant disease
R. Cox, T. Musial, S. Stafford & O.H.B. Gyde
Departments of Surgery & Haematology, East
Birmingham Hospital, Birmingham, B9 5ST
The Anaemia of Chronic Disorder (ACD) is
commonly associated with neoplastic (NG) disease.
Investigation of Erythropoietin (Ep) levels using
whole animal assays has given variable and
conflicting results in this condition. In the present
study Ep levels were measured using the Foetal
Mouse Liver Assay in 40 patients with NG disease
(33 small cell cancer of bronchus, 7 other NG) with
a range of haemoglobin (Hb) levels and 19 normal
controls. Anaemia and iron status were determined
using full blood count, serum iron, transferrin and
ferritin levels and bone marrow cytochemistry.
Twelve patients had Hb <11 gdl - and the
features of ACD. Thirteen other patients with NG
had Hb > 12.5 gdl - with some features of ACD
but no evidence of a specific deficiency or marrow
infiltration. Mean Ep level for the patients with Hb
<llgdl- and ACD was 0.22iuml-' which was
significantly lower than for the controls
0.31iuml-1 (P<0.02). The patients with NG and
Hb >12.5gdl-l had a mean Ep level of
0.26iuml-' These data support the concept that
lack of an appropriate Ep response to a fall in Hb
is one factor in the genesis of ACD of malignancy.
Results of chronic lymphocytic and other leukaemias
in a four-day tumour chemosensitivity assay
A.G. Bosanquet, M.C. Bird & E.D. Gilby
Royal United Hospital, Combe Park, Bath, Avon
We are investigating the use of a relatively rapid
and simple tumour cell assay as a means of
predicting tumour response to cytotoxic drugs. The
whole white cell fraction from blood or bone
marrow is isolated by centrifuging over 1.090gml-'
Ficoll/Isopaque and washed. The cells are set up at
2.5 x 105/tube in RPMI 1640 medium with 10%
foetal calf serum. Drugs are added for either 1 h or
continuously and the cells are incubated for 4 days
at 37°C. A solution of a vital dye (fast green FCF)
is added to stain the dead cells and they are
cytocentrifuged. The live cells are counterstained
with a modified haematoxylin/eosin or
Romanowsky stain. Tumour cells are identifiable
and are counted as a percentage of all cells. For
drug-treated samples, the percent live tumour cells
is calculated and expressed as a percentage of that
in control samples (%TCV). Optimal drug
concentrations for use in vitro have been determined
for chlorambucil (2pgml-1), 4-hydro-
peroxycyclophosphamide (2pgml-), vincristine
(0.1 pg ml -) and prednisolone (0.5pgml-1).
Other drugs are also under investigation.
From 20-200 control and drug-treated
tubes are set up from each sample received
and the number of cells has never been a limiting
factor. Thirty-seven of 45 tests (82%) undertaken
with CLL have been technically successful. From
these, 11 assay results could be correlated with in
vivo response. Two were sensitive both in vitro and
in vivo and nine were resistant in vitro and in vivo.
Simulation of genetic effects in white rats perinataily
exposed tofusarium mycotoxins
R. Schoental
Dept. Pathology, Veterinary College, University of
London, London NW] OTU
The great susceptibility of rapidly growing tissues
to carcinogens is well documented. The differential
susceptibility is often reflected in the striking
differences between the effects of various
xenobiotics on pregnant or lactating rats, and on
their offspring. The latter may become affected by
exposing the mother to doses of noxious agents,
which leave the adult unscathed, as was first
demonstrated using the hepatotoxic and
hepatocarcinogenic pyrrolizidine alkaloids. In
continuation of these studies, other substances were
used which include the carcinogenic secondary
metabolites of Fusarium. When relatively large
doses of the oestrogenic zearalenone. were given,
either singly or combined with the trichothecene,
T-2 toxin, to pregnant and/or lactating white rats,
various tumours, benign and malignant, were found
both in the treated mother-rat, and also in the
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endometrial neoplasms in mother and daughter rats
appears to simulate familial tumours due to genetic
factors.
Manipulation of hepatic y-glutamyl transpeptidase
activity in control and AFB1-fed animals to study its
role in detoxification of carcinogens
M. Manson, G.E. Neal & E. Moss
MRC Toxicology Unit, Carshalton, Surrey, SM5
4EF
A new tumour marker system using primary cultures
of rat hepatocytes
I. Hayashi & B. Carr
Departments of Cytogenetics & Medical Oncology,
City of Hope National Medical Center, Duarte,
California 91010, U.S.A.
Primary monolayer cultures of adult rat
hepatocytes do not conventionally proliferate.
However, when hepatocytes from male F344 rats,
200-230gwt, were cultured in the presence of the 3
hormones (3H) glucagon 0.2jugml-', insulin
0.2jugml-, and EGF lOngml-1, DNA synthesis
(DNA-S) occurred with a peak at 72-96h after
plating. The extent of DNA-S was cell density
dependent, exhibiting a peak at 3 x IO' cells/35mm
diameter culture dish. Substratum was also
important, since gelatin coating of the dishes
induced greater DNA-S than fibronectin or plastic.
Both glucagon and EGF displayed a linear dose
response which then plateaued. However, insulin
had a more complex response, with inhibition at
higher doses. A large number of other hormones
were tested, but added little to the above, except
hydrocortisone which caused an inhibition of DNA-
S. The effects of normal rat serum (NRS), calf
serum, and normal human serum were tested in this
system at 0.1-20%. All elicited DNA-S at 0.1-1.0%
similar to that produced by 3H alone. However,
above 3%, the only observable effect was an
inhibition of DNA-S compared to 3H alone.
Human plasma was similar to human serum, but
human platelet-derived growth factor consistently
inhibited DNA-S at 1.25-lOjugml-'. No difference
was observed when NRS was compared to serum
from rats containing regenerating livers at 1-36h
after partial hepatectomy. However, the serum from
rats which were fed the hepatocarcinogen 2-AAF
induced a 4-fold increase in the DNA-S compared
to NRS, starting at 1 week after carcinogen
administration. The 105,000 xg supernatant of 2-
AAF livers also increased the level of DNA-S in the
test hepatocytes compared to the similar extract
from normal liver. These presumptive tumour
growth factor(s) are now being further
characterized.
Gamma glutamyl transpeptidase (yGT) found in the
bile duct epithelium in normal adult rat liver,
appears in foci of hepatocytes (so-called
preneoplastic lesions) in animals exposed to one or
more of a wide range of carcinogens. Among the
proposed functions of yGT in normal liver are
involvement in maintenance of intracellular
glutathione levels and also in breakdown of
glutathione conjugates in the first stage of
mercapturic acid formation. The function of the
enzyme in preneoplastic foci is poorly understood,
although such hepatocytes may be more resistant to
cytotoxic effects of the carcinogen. In the present
study bile was collected from control adult male
Fischer 344 rats and from animals fed a diet
containing 4ppm AFB1 for at least 10 weeks.
Fifteen mins before cannulation some animals
received 11 mg AT125 i.p. and immediately prior
to bile collection some animals from each group
received i.v. 5 jiMkg-1 AFB1. yGT activity was
examined histochemically in liver and quantitatively
in liver and bile. The enzyme was present in the bile
duct epithelium in control animals and also in
numerous foci in fed animals (5-lOx control levels).
yGT activity could be measured in bile from
control and fed animals but no particular pattern
emerged. In animals treated with AT 125, a specific
inhibitor of yGT, no. enzyme activity was visible
histochemically in any lobe of the liver and no
activity could be measured in liver homogenates or
in bile. yGT activity was also measured in female
rats (which are more resistant to toxic and
carcinogenic effects of AFB1) and found on average
to be 2 x that of males, present in hepatocytes as
well as bile ducts. These animals were then used to
study the effect of altered yGT activity, particularly
in hepatocytes, on the pattern of AFB1-conjugates
excreted into bile following a single i.v. dose of the
carcinogen as described in the next abstract.
The effect of manipulation ofyGT on the biliary
excretion of aflatoxin B,-conjugates
E.J. Moss, G.E. Neal & M. Manson
MRC Toxicology Unit, Carshalton, Surrey SM5 4EF
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intermediate of the carcinogen aflatoxin B1 (AFB1),
has been prepared in vitro. 1H n.m.r. and mass
spectrometry identified the conjugate as the 8,9-
dihydro-8(S-glutathionyl)-9-hydroxy aflatoxin B1
(AFB1-GSH). This conjugate was shown to be a
substrate for y-glutamyl transpeptidase (yGT) in
vitro demonstrating the presence of a free,
transferable y-glutamyl moiety. Incubations with a
hepatoma cell line rich in GGT resulted in the
disappearance of AFB1-GSH on HPLC analysis
and the appearance of a new material, with a longer
retention time, identified as the cysteinyl-glycl
conjugate of AFB, (AFB1-Cys Gly). This
transformation was inhibited by the specific GGT
inhibitor, AT 125. In vivo, following i.v. injection of
AFB1 to control male Fischer 344 rats (5 iuMkg-1),
AFB1-GSH was detected in the bile as a major
AFB1 metabolite over the first 2h. Although the
conjugate passes through an area of the liver rich in
GGT the rate of conversion of AFB1-GSH to
AFB1-Cys Gly at this dose level was very low
(AFB1-GSH: AFB1-Cys Gly 10:1). However, in
animals which had been fed 4 ppm AFB1 for a 12-
week period prior to the experiment, the pattern of
biliary excretion was dramatically altered. The
AFB1-Cys Gly levels were elevated such that AFB1-
GSH:AFB,-Cys Gly ratios of 1:1 were recorded.
Administration of AT 125 to the animals
immediately prior to the experiment inhibited
conversion to AFB1-Cys Gly and the amount
detected was approximately < to levels in control
animals (AFB,-GSH:AFB,-Cys Gly
- 40:1). These
results show the influence of altered GGT levels on
the subsequent metabolism of carcinogens and
provide information on the site of metabolism of
carcinogens in the preneoplastic liver.
Investigations of mechanisms responsible for
alterations in drug sensitivities occurring after
long-term radiation exposure
A.S. Bellamy & B.T. Hill
Laboratory of Cellular Chemotherapy, Imperial
Cancer Research Fund, London, WC2A 3PX
Alterations in response to chemotherapeutic agents
after long-term radiation (DXR) exposure of
mammalian tumour cell lines in vitro, have been
reported previously (Bellamy & Hill, (1982), Br. J.
Cancer, 45, 640). For DXR-pretreated HN-1 cells
(derived from a squamous cell carcii.oma of the
tongue), the most marked changes noted were
significantly reduced sensitivities to 24h exposures
to vincristine or VP16-213, and a significantly
increased sensitivity to 5-fluorouracil (24h
exposure), compared with responses to untreated
parent cells. Studies of cellular [3H]-vincristine
transport showed no difference in drug uptake by
radiation-pretreated and parent HN-1 cells, despite
the marked resistance of the radiation-treated line
to vincristine. Alkaline sucrose gradient
sedimentation profiles showed evidence of single
strand breaks in DNA after a 24h exposure to
VP16-213. However, these were present in both
parent and radiation-pretreated cells, which implies
that such lesions may not be related to the
differential cytotoxic responses observed. Cellular
levels of two of the enzymes involved in 5-
fluorouracil metabolism were determined.
Thymidine kinase activity was comparable in both
untreated and radiation pretreated cells. The
activity of thymidylate synthetase, however, was
significantly decreased in radiation-pretreated cells.
This may be associated with the increased
sensitivity of these cells to 5-fluorouracil. If
confirmed, this finding of specific DXR-induced
cellular changes, associated with altered drug
responses has major implications for the combined
modality treatment of human cancers.
Studies on fluorescent probes for hypoxic cells
A.C. Begg, N.J. McNally, R.J. Hodgkiss & P.
Wardman
CRC Gray Laboratory, Mount Vernon Hospital,
Northwood, Middlesex HA6 2RN
Certain nitroimidazoles have been found to undergo
nitroreduction with subsequent binding in hypoxic
cells, but not in oxic cells. We have attempted to
utilize this differential by developing compounds
which become fluorescent on nitroreduction, a
process which occurs only in hypoxic cells. Such
compounds could, in principle, be used to
quantitate and separate hypoxic cells in tumours
using a flow cytometer/cell sorter. To date, two
compounds have been studied, viz. Eosin B and
nitroacridine. V79-379A cells grown in suspension
culture were incubated with the drug in air and
hypoxia and tested for fluorescence using an Ortho
Cytofluorograph, System 50H. Fluorescence
histograms were obtained for cells incubated with
the compounds at different concentrations for
various times. With 5004uM Eosin B the mean
fluorescence of hypoxic cells was greater than that
for oxic cells for incubation times up to 3h;
however, there was considerable overlap of the
fluorescence histograms. With nitroacridine, almost
complete separation of the fluorescence histograms
for oxic and hypoxic cells was obtained and at572 ABSTRACTS OF INVITED AND PROFFERED PAPERS
concentrations showing minimal cytotoxicity. In
multicellular spheroids of V79-171 B cells incubated
with nitroacridine and grown in medium gassed
with air, a proportion of cells were fluorescent
indicating the presence of hypoxic cells. The
proportion depended upon the size of the spheroids
and the frequency of changing their growth
medium. A comparison of the fluorescent fraction
with the radiobiologically determined hypoxic
fraction will be made.
Antimetastatic effect of cimetidine against the C3H
mouse mammary adenocarcinoma
M. Penhaligon, J. Anthoons', D. Pilkington, R.A.
Wolstencroft' & A.H.W. Nias
Richard Dimbleby Department of Cancer Research
and 1Immunology Department, St. Thomas's
Hospital Medical School, London SE] 7EH
There are no effective antimetastatic agents that are
not also highly toxic. Osband et al. (1981), Lancet, i,
636, found that Cimetidine prolonged survival and
slowed metastatic development in mice bearing the
Lewis lung carcinoma. They suggested this was due
to blockade of the suppressor cell system by
Cimetidine, a histamine-2 receptor antagonist.
Using the C3H mouse mammary adenocarcinoma
we have examined the effect of Cimetidine on
survival, metastasis development and the response
of spleen lymphocytes to mitogens. Lung metastases
were produced by implanting tumours s.c. on the
back and allowing them to grow to a mean
diameter of 5.3mm when they were ablated with 90
Gy x-irradiation. Metastases became detectable
after about 40 days. Cimetidine was given in the
drinking water (10mgml-1) from the time of
irradiation until the end of the experiment.
Cimetidine reduced the number of mice dying from
metastases from 47% (controls) to 24%. Cimetidine
also slowed metastatic development. The response,
in terms of thymidine incorporation, of spleen
lymphocytes from Cimetidine treated and control
mice to the T-cell mitogen Phytohaemagglutinin
and the B-cell mitogen Lipopolysaccharide was
depressed or enhanced according to mitogen dose
and time of assay during the course of Cimetidine
treatment and metastatic development. The
mechanism of action of Cimetidine's antimetastatic
effect remains unclear.
Site-specific growth of rat tumours
N. Willmott, J. Newton' & K.C. Calman
Department of Oncology, University of Glasgow, and
'Department of Haematology, Western Infirmary,
Glasgow
Whilst much effort has been directed towards
quantifying tumour growth in the lungs of
experimental animals, few studies have compared
growth in pulmonary tissue with growth at other
sites. Consequently, in these studies we have
examined the growth of tumours Mc7, Mc4OA,
Walker 256 and Sp 24 following i.v. and s.c.
injection into Nottingham Wistar rats, using a
method that is objective, amenable to statistical
analysis and accurately reflects numbers of
clonogenic tumour cells. The technique involved
recording incidence of tumour growth following i.v.
and s.c. injection of graded doses of cells from each
tumour and calculation of TD-50 values. It was
found that Mc7 and Sp 24 cells were significantly
more tumourigenic following i.v. injection than s.c.
injection, whereas the converse was true of Walker
256 cells. Tumourigenicity of Mc4OA cells was not
significantly different following i.v. and s.c. injection.
Growth of all tumours after i.v. injection was
confined to the lungs. Experiments with
radiolabelled tumour cells injected i.v. revealed that
those tumours exhibiting increased tumourigenicity
following i.v. injection, relative to s.c. injection,
appeared better able to survive the attrition
generally seen when tumour cell suspensions are
injected into the blood stream. Further experiments
indicated that association of tumour cells, either
with platelets or other tumour cells, was correlated
with higher tumourigenicity following i.v. injection
relative to s.c. injection.
Spontaneous and experimental metastasis of primary
mammary tumours: Back titration of cell shedding
J.E. Price & D. Tarin
Nuffield Department of Pathology (University of
Oxford), John Radcliffe Hospital, Oxford
Spontaneous mammary tumours of mice differ in
metastatic colonisation potential, some producing
many pulmonary deposits (high colonisation
potential-HCP), others producing few or none
(low colonisation potential LCP) after intravenous
inoculation (Tarin & Price (1979), Br. J. Cancer, 39,
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have independent colonisation potentials, indicating
that this is a property of the neoplasm rather than
the host. Serial dilution experiments show that
HCP tumour cells still produce large numbers of
lung deposits when the dose is reduced to 103 or
104 viable cells. The standard assay dose of 5 x 105
cells is, therefore, 50 times in excess of that required
for the definitive colonisation grade. Differences
between HCP and LCP tumours remain stable over
a wide range of doses, although are not absolute;
some LCP tumours can colonise the lungs heavily,
but only at doses 250 times greater than that
required for HCP tumours to give a similar result.
The incidence of spontaneous metastasis in a
sample of 200 primary mammary tumours in
C3H/AVY mice was found to be 33%. When
inoculated i.v., cells from some of these metastatic
tumours had HCP and others LCP and the degree
of spontaneous metastasis did not always coincide
with the i.v. result. From the assayed colonisation
potential of a tumour, the degree of spontaneous
metastasis and knowledge of dose response, one can
back-titrate the degree of cell shedding from a
particular tumour. For example, tumours which
were of LCP by i.v. assay but had produced
numerous pulmonary deposits spontaneously must
have shed enormous numbers of cells into the
blood. Conversely, those tumours of HCP which
produced few spontaneous metastases must have
shed exceedingly few cells (Price et al. (1982),
Invasion & Metastasis, 2 (in press).
Degradation of basement membrane collagens by
disseminating tumours in three vertebrate species
S.E. Shields, D.J. Ogilvie, R.G. McKinnell & D.
Tarin
Nuffield Department of Pathology (University of
Oxford), John Radcliffe Hospital, Oxford
Observations on tumour invasion and metastasis
have demonstrated extensive destruction of the
adjacent connective tissues and basement
membranes. The deduction that the breakdown of
collagen is caused by the local extracellular release
of neutral proteases is supported by studies
demonstrating the secretion of a specific collagenase
active against type I (fibrous) collagen by murine
mammary tumours (Tarin et al. (1982), Br. J.
Cancer, 46, 266). However, it has been found that
collagen types IV and V, which are structurally
distinct from collagen type I, are resistant to this
previously isolated collagenase. We have, therefore,
looked for secretion of collagenases capable of
F
digesting these components of basement
membranes.
Types IV and V collagen were obtained from
human placentae by pepsin digestion followed by
salt fractionation. Supernatants from explant
cultures of murine mammary tumours, human
breast and endometrial carcinomas, and amphibian
renal tumours were tested for protease activity
against these collagenous substrates. Breakdown of
substrates and appearance of specific reaction
products were displayed by polyacrylamide gel
electrophoresis. Confirmation that substrate
cleavage was due specifically to collagenase activity
was obtained by its inhibition in the presence of
EDTA. The supernatants from all three species
studied were capable of digesting type IV collagen;
one human breast tumour supernatant also digested
type V collagen. The degree of substrate cleavage
differed between tumours and activity against types
IV and V collagen varied independently indicating
the presence of two separate enzymes. These
findings support the interpretation that the
destruction of collagen is an important and general
mechanism underlying tumour invasion and
metastasis in several species.
Changes in tumour cell kinetics with distance from a
blood vessel
B. Jones & R.S. Camplejohn
Richard Dimbleby Department of Cancer Research,
St. Thomas's Hospital Medical School, London SE].
7EH
Cell kinetic variations within a tumour due to a
variety of factors including vascular proximity may
have important implications for cancer therapy. In
this study the stathmokinetic effect of Vincristine
(VCR) was used to determine cell birth rates (kB) at
increasing distances from central blood vessels
occurring in corded areas of transplantable C3H
mouse mammary tumours. This method has many
advantages over tritiated thymidine techniques used
by other authors in similar situations. For example,
the length of time required to perform fraction
labelled mitosis or continuous labelling experiments
is such that migration of tumour cells may seriously
complicate the results. In contrast a metaphase
arrest experiment can be completed within 3 hours,
thus minimizing the effect of cell migration. This
method, when carefully performed, yields a direct
estimate of kB and also provides 95% confidence
limits for each result. kB was estimated by counting
1000 cells in each of the following zones: A
(proximal to vasculature), B (intermediate) and C574 ABSTRACTS OF INVITED AND PROFFERED PAPERS
(furthest from vasculature and adjacent to necrosis).
A progressive reduction in native mitotic index, cell
birth rates and calculated growth fraction was seen
from zone A to zone C. Mean kB expressed as new
cells/1000 cells/hour with 95% confidence limits in
brackets for zone A, B and C respectively were: 29.9
(19.1-40.7); 18.7 (9.6-27.8); 4.8 (1.9-7.7). The
estimated duration of mitosis remained fairly
constant in each zone (A-47 min, B-44 min and
C 56 min). No ana- or telophases were seen in
zone C, demonstrating that diffusion of VCR was
sufficient to cause complete metaphase arrest. These
results demonstrate a clear inverse relationship
between cell proliferation and distance from a blood
vessel.
Oestrogens, malignant disease and folate metabolism
J.A. Blair, P.A. Barford, A.E. Pheasant, A.E. Guest,
C. Eggar & G.D. Oates
Department of Chemistry, University of Aston in
Birmingham, Birmingham B4 7ET and The General
Hospital, Steelhouse Lane, Birmingham, B4 6NH
In man and the rat with malignant disease folate
metabolism alters so as to reduce folate breakdown
by scission and to increase the proportion of folates
present as 10-formyltetrahydrofolate derivatives.
Thus the concentration of the folate coenzymes
crucial for the synthesis of purines and thymidylate
for RNA and DNA increases. In oestrogen-
sensitive human breast tumours but not in human
gut tumours dihydropteridine reductase activity, an
enzyme reducing folate scission, is significantly
increased compared to adjacent apparently normal
tissue. Oral administration of diethylstilboestrol to
female rats significantly reduces folate breakdown
and greatly increases the proportion of 10-
formyltetrahydrofolate. Thus oestrogen appears to
alter folate metabolism to a pattern required for
proliferating tissue. Anti-oestrogen therapy of
breast tumours may act by altering folate
metabolism.